Yüklüyor......
Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature
Multiple myeloma (MM) accounts for 1.5% of all cancers and approximately 13% of all hematologic malignancies. Therapy for MM has substantially improved after the application of immunomodulatory drugs and proteasome inhibitors. The first proteasome inhibitor, bortezomib, can be considered a major mil...
Kaydedildi:
| Yayımlandı: | Int J Clin Exp Med |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
e-Century Publishing Corporation
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4694525/ https://ncbi.nlm.nih.gov/pubmed/26770625 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|